Straits Times Index
3,313.48 +8.49 (+0.26%) Nikkei
38,787.38 -132.88 (-0.34%) Hang Seng
19,553.61 +177.08 (+0.91%) FTSE 100
8,420.26 -18.39 (-0.22%) Bitcoin USD
66,858.09 +1,503.03 (+2.30%) CMC Crypto 200
1,350.62 -23.22 (-1.69%)
Roche Holding AG (RHHVF)
| Previous close | 261.27 |
| Open | 261.27 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 260.00 - 263.86 |
| 52-week range | 233.12 - 323.78 |
| Volume | |
| Avg. volume | 10,066 |
| Market cap | 210.628B |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | 16.57 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 10.86 (4.16%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- Zacks
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
- Barrons.com
Dow Hitting 40,000 Is Good but Look Here for Where Markets Are Headed, and 5 Other Things to Know Today.
Reddit content is coming to OpenAI’s chatbot, Roche’s weight-loss drug impresses analysts in early-stage trials, and other news to start your day.
- Benzinga
Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate
Thursday, Genentech, a unit of Roche Holdings AG (OTC:RHHBY), released results from the Phase 1b trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes. The study found that a once-weekly subcutaneous injection of CT-388 over 24 weeks resulted in significant weight loss in healthy adults with obesity compared to placebo. The weight loss achieved with CT-388 was clinically meaningful, with a mean placebo-adjusted weight loss of 18.8% (p
